Citi Initiates Coverage on AIG with Neutral Rating, $85 Price Target

Citi initiated coverage of AIG with a Neutral rating and $85 price target. The firm expects pricing and reinvestment tailwinds to ease but for earnings to remain resilient. Citi sees more opportunities for upside in underwriters relative to brokers. Top ideas include Arch Capital, Aspen Insurance, Brown & Brown, Chubb, Ryan Specialty, and RenaissanceRe.

Citi has initiated coverage of AIG (NYSE: AIG) with a Neutral rating and a price target of $85, reflecting the firm's expectations for pricing and reinvestment tailwinds to ease while maintaining resilient earnings. The report highlights potential upside opportunities for underwriters relative to brokers, with top picks including Arch Capital (NASDAQ: ARCC), Aspen Insurance (NYSE: ASPN), Brown & Brown, Chubb (NYSE: CB), Ryan Specialty (NYSE: RYN), and RenaissanceRe (NYSE: REN).

Citi's analysts anticipate that pricing and reinvestment tailwinds will ease, which could impact AIG's financial performance. However, they remain optimistic about the company's earnings resilience. The report also suggests that underwriters may offer more upside potential compared to brokers, which could benefit AIG's stock performance.

The top ideas listed in the report are Arch Capital, Aspen Insurance, Brown & Brown, Chubb, Ryan Specialty, and RenaissanceRe. These companies are expected to perform well due to their strong market positions and growth prospects. Citi's analysis indicates that these companies have the potential to outperform the broader market, making them attractive investment opportunities.

For investors and financial professionals, Citi's Neutral rating and price target provide a balanced view of AIG's current situation and future prospects. The report highlights the potential challenges and opportunities that AIG may face in the coming months, as well as the specific companies that Citi believes are well-positioned to benefit from the current market conditions.

References:
[1] https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-announces-closing-of-upsized-85-million-private-beg49f5igeth.html
[2] https://www.tradingview.com/news/tradingview:2ffe0ac0a503c:0-trinity-capital-ceo-kyle-steven-brown-buys-3-200-shares/